At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 14 enrolled
Drug / intervention
Enoxaparin sodiumbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Dose Study to Examine the Within Subject Variability of Clexane® (80 mg) s.c. in Healthy Adult Subjects Under Fasting Conditions
In Brief
A Phase 1 clinical trial evaluating Enoxaparin sodium for Clexane is Administered to Healthy Volunteers. Completed, enrolled 14 participants across 1 site.
Detailed Summary
Primary: To examine the within subject variability of Clexane (80 mg) in healthy male and female volunteers administered subcutaneously (s.c.) as a single dose, in two periods, under fasting conditions. Secondary: To monitor safety during the Treatment Periods.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartMar 2014
Primary CompletionMar 2014
First PostedMar 2014
TodayJul 2026
First PostedMar 7, 2014
Enrollment StartMar 1, 2014
Primary CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 12.3 years ago
Interventions
Enoxaparin sodiumbiological
comparison of 2 different administration of drug